ABBV vs AVGO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Broadcom Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Broadcom Inc. · Technology
$371.59
-45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
AVGO trades at a lower forward P/E
(70.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
AVGO |
| Current Price |
$197.69 |
$371.59 |
| Fair Value Estimate |
$210.22 |
$204.37 |
| Upside to Fair Value |
+6.3%
|
-45.0%
|
| Market Cap |
$349.7B |
$1,761.8B |
| Forward P/E |
83.3x
|
70.7x
|
| EV / EBITDA |
23.4x
|
46.7x
|
| Price / Sales |
5.7x
|
25.9x
|
| Price / FCF |
18.7x
|
61.1x
|
| Revenue Growth YoY |
+10.0%
|
+7.2%
|
| Gross Margin |
70.2%
|
67.1%
|
| Operating Margin |
26.7%
|
40.9%
|
| Return on Equity |
-361.6%
|
32.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
1.64%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a strong competitive moat driven by scale, diversification, and aggressive M&A under CEO Hock E. Tan. The company has demonstrated robust revenue growth, particularly in semiconductor solutions and infrastructure software segments, with a 25% year-over-year increase recently and a five-y…
Accumulation Zones
| Metric |
ABBV |
AVGO |
| Zone Low |
$157.66 |
$153.28 |
| Zone High |
$178.69 |
$173.71 |
| In Buy Zone? |
No
|
No
|